Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ5082 vs Eculizumab in PNH
NCT07177859Phase 3Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NTQ5082 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
NTQ5082
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07177859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177859.